WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company’s determination to advance its mission of developing accessible, life-saving therapeu ...

Core Insights - Tevogen Bio reported a significant reduction in net loss, decreasing from $56.8 million in 2023 to $4.3 million in 2024 for the nine months ended September 30 [1] - The company improved its financial position by nearly eliminating its liabilities, reporting $10.5 million as of September 30, 2024, down from $99.9 million as of December 31, 2023 [1][4] - Tevogen's intellectual property and product assets are valued internally at over $10 billion, but these are not reflected on the balance sheet due to US GAAP accounting rules [3][5] - The company has sufficient capital to fund operations for at least the next 33 months, supported by a loan agreement [4] Financial Performance - Tevogen's net loss for the nine months ended September 30, 2024, was $4.3 million, a significant improvement from $56.8 million in the same period of 2023 [1] - The company reported a substantial decrease in liabilities, from $99.9 million at the end of 2023 to $10.5 million by September 30, 2024 [1][4] Intellectual Property and Assets - Tevogen's internally developed intellectual property and product assets are valued at over $10 billion based on discounted cash flow models, but are not included on the balance sheet due to US GAAP restrictions [3][5] - The company holds multiple granted patents and has several pending patents related to its proprietary immunotherapy technologies and artificial intelligence platforms [6] Ownership Structure - Approximately 78% of equity is retained by Tevogen's officers, which is significantly higher than the industry average of 4% [5] - Key employees have also been granted substantial restricted stock units, reflecting a belief in shared ownership of the company's success [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share TVGN The Nasdaq Stock Market LLC Warrants, each exercisable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSIT ...

Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is considerably lower than the industry average [1][3] - The company focuses on off-the-shelf, genetically unmodified T cell therapeutics aimed at treating infectious diseases and cancers, emphasizing a disciplined and sustainable business model [2][4] - Tevogen's leadership is committed to preserving shareholder value while navigating the need for capital, with potential equity dilution from warrant conversion at a strike price of $11.50 per share, which could yield over $200 million [1][3] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company utilizing CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for various diseases, addressing significant unmet medical needs [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier in medicine, necessitating innovative business models to sustain medical advancements [5]

Core Insights - Tevogen Bio has developed a significant asset portfolio since its founding in 2020 while maintaining expenditures under $40 million, which is a fraction of the industry norm [1][3] - The company focuses on building a disciplined and sustainable business model in the biotech sector, particularly in immunotherapy for infectious diseases and cancers [2][4] - Tevogen's leadership emphasizes the importance of preserving shareholder value and being cautious about equity dilution when considering financing options [3][4] Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf, genetically unmodified T cell therapies targeting infectious diseases, cancers, and neurological disorders [4][5] - The company has reported positive safety data from its proof-of-concept clinical trials and owns key intellectual property assets, including three granted patents and numerous pending patents [4] - Tevogen's leadership believes that accessible personalized therapeutics represent the next frontier of medicine, necessitating innovative business models to sustain medical innovation [5]

WARREN, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen. In tandem with this announcement, Tevogen Bio reaffirms ...

Core Viewpoint - Tevogen Bio has appointed Anthony Tarantino as its new Patient Advocate, leveraging his extensive experience in firefighter safety and community advocacy to enhance patient-centered healthcare initiatives, particularly for immunocompromised cancer patients and those suffering from Long COVID [1][3][4]. Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, genetically unmodified T cell therapeutics for treating infectious diseases, cancers, and neurological disorders [5][6]. - The company aims to address significant unmet needs in large patient populations and believes that sustainability and commercial success depend on ensuring patient accessibility through advanced science and innovative business models [5]. Leadership and Advocacy - Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters Association of New Jersey, where he advanced policies for firefighter health and safety, including legislation for regular cancer screenings [2][3]. - His advocacy work is rooted in public health principles, focusing on access to life-saving resources and legislative engagement, which aligns with Tevogen's mission [3][4]. Current Initiatives - Tarantino's appointment is timely as Tevogen advances its investigational therapy, TVGN 489, aimed at treating SARS-CoV-2 in cancer patients and those with Long COVID [4]. - The company has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned, including three granted patents and several pending patents [5].

PRINCETON JUNCTION, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Alpha Capital Corp ("Alpha"), a global merchant bank, is pleased to announce that it has been retained as the exclusive financial advisor to CD8 Technology Services, LLC ("CD8 Technology") in connection with financing a real estate facility whose primary focus is developing and manufacturing biologic products for cell therapy. By eliminating barriers to entry, in terms of capital and time to build GMP capabilities at scale, this venture will expedi ...

CD8 Technology Services, LLC ("CD8 Technology") to provide turn-key facility for Tevogen Bio Reinforces Tevogen Bio's commitment to preserving shareholder value Expected to further enhance Tevogen Bio's ambitious growth agenda WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, took si ...

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today provided additional guidance on the first clinical product of the company's proprietary ExacTcell™ technology, TVGN 489, designed to treat SARSCoV-2 infections in immunocompromised oncology patients, and a subgroup of patients w ...